Today: 20 May 2026
Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious
30 December 2025
1 min read

Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

NEW YORK, December 30, 2025, 14:33 ET — Regular session

  • Accenture shares dipped in thin year-end trading as a brokerage cut its price target but kept a buy rating.
  • U.S. stocks were muted after Federal Reserve minutes highlighted divisions over the path for rates.
  • Investors are looking ahead to Accenture’s next earnings update in March.

Accenture plc shares were down about 0.5% on Tuesday, drifting lower in a quiet year-end session after Argus lowered its price target on the IT services company while maintaining a buy rating.

The move matters because Accenture is widely treated as a read-through on corporate technology spending, and late-December liquidity is thin. In that backdrop, even routine changes in analyst targets can move large-cap consulting names more than usual.

Traders were also navigating a fresh macro signal after Federal Reserve meeting minutes showed policymakers split over how quickly to keep easing policy, a debate that can feed into valuations for growth-linked stocks and the pace of client spending on big transformation projects.

Accenture was trading at $270.06, down $1.28 from its prior close. The stock traded between $269.54 and $272.25.

MT Newswires reported that Argus cut its price target on Accenture to $335 from $370, while keeping a buy rating. A price target is an analyst’s estimate of where a stock may trade over the next 12 months.

Broader market moves stayed restrained. The S&P 500 and Nasdaq were little changed in choppy trading, with investors repositioning out of heavyweight technology after a recent run, according to Reuters. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Peers were mixed. IBM and Cognizant Technology Solutions were both down around 0.7% to 0.9%, while Booz Allen Hamilton was slightly higher.

The latest analyst move comes less than two weeks after Accenture reported quarterly results that beat Wall Street revenue expectations, helped by demand tied to AI-driven IT services. Accenture forecast second-quarter revenue of $17.35 billion to $18.0 billion, with the midpoint below analysts’ expectations, according to LSEG data cited by Reuters.

The Fed minutes released Tuesday showed that even some officials who supported the December rate cut saw the decision as “finely balanced,” while others worried progress toward the 2% inflation goal had stalled, Reuters reported. The minutes also flagged January 9 and January 13 as dates when delayed jobs and consumer price data for December are due, with the Fed’s next meeting set for January 27-28. Reuters

For Accenture, the next major scheduled company catalyst is its second-quarter fiscal 2026 earnings call on March 19, the company’s investor FAQ page shows.

Until then, traders are likely to take their cues from rate expectations, year-end flows and any fresh signs of how quickly clients are signing large multi-quarter programs — a key driver for consulting firms’ bookings, which represent future contracted work.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
KLA stock dips as China’s 50% domestic chip-tool rule rattles semiconductor equipment names
Previous Story

KLA stock dips as China’s 50% domestic chip-tool rule rattles semiconductor equipment names

Goldman Sachs stock slips after Fed minutes — here’s what traders are watching next
Next Story

Goldman Sachs stock slips after Fed minutes — here’s what traders are watching next

Go toTop